A new treatment for Alzheimer’s disease has demonstrated a substantial reduction in cognitive decline, according to findings from a recent international clinical trial. The therapy, administered as a low-dose injection twice yearly, slowed the deterioration of memory and thinking abilities by 54 percent over nearly two years among patients with early-stage Alzheimer’s.
The trial involved 416 participants and compared three different dosing regimens of the drug diranersen against a placebo. Patients receiving the lowest dose showed the most notable benefit, exhibiting a 54 percent slower decline on a standard cognitive assessment after 96 weeks. When evaluating broader measures that include daily functioning, the treatment group experienced a 38 percent reduction in decline.
Diranersen employs gene-silencing technology designed to reduce the production of tau, a protein strongly associated with Alzheimer’s pathology. The accumulation of tau tangles within brain cells is linked to cell death and disease progression. The trial is the first to demonstrate a decrease in tau levels alongside clinical improvement, marking a significant milestone in Alzheimer’s research.
Professor Jeffrey Cummings, a co-author of the study, presented the results at the Clinical Trials on Alzheimer’s Disease conference in Boston, stating that the therapy effectively “reversed Alzheimer pathology” through the removal of tau tangles. This approach targets the disease at its biological source, contrasting with previous treatments that have focused primarily on amyloid plaques, another hallmark of Alzheimer’s found between brain cells.
The trial’s success has generated considerable interest among patients, with reports indicating a strong demand in the United Kingdom for participation in upcoming trials. Recruitment for British patients is anticipated to begin in the spring.
Alzheimer’s is believed to arise from a combination of multiple damaging biological processes, including the buildup of amyloid plaques and tau tangles, both of which disrupt brain function. The diranersen trial represents a promising advance by addressing the tau component directly.
While further studies are needed to confirm long-term benefits and safety, these results provide hope for a new era of disease-modifying therapies in Alzheimer’s care, offering patients and clinicians a potential tool to slow the progression of a condition that affects millions worldwide.
